Overview

Apixaban in Subjects With Peritoneal Dialysis

Status:
Unknown status

Trial end date:
2020-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the pharmacokinetics of a single oral dose of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal renal function.

Phase:

Phase 1

Details

Lead Sponsor:

University Hospital, Caen

Collaborator:

University Hospital, Rouen

Treatments:

Apixaban